BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morita Y, Murayama H, Odawara M, Bauer M. Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database. Diabetol Metab Syndr 2019;11:90. [PMID: 31695754 DOI: 10.1186/s13098-019-0486-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Baxter M, Morimoto Y, Tamiwa M, Hattori M, Peng XV, Lubwama R, Maegawa H. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes. Diabetes Ther 2020;11:1481-96. [PMID: 32445125 DOI: 10.1007/s13300-020-00836-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Terauchi Y, Yabe D, Kaneto H, Amano A, Baxter M, Watanabe D, Watada H, Inagaki N. Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials. Diabetes Obes Metab 2020;22 Suppl 4:35-47. [PMID: 33404200 DOI: 10.1111/dom.14139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kohsaka S, Morita N, Okami S, Kidani Y, Yajima T. Current trends in diabetes mellitus database research in Japan. Diabetes Obes Metab 2021;23 Suppl 2:3-18. [PMID: 33835639 DOI: 10.1111/dom.14325] [Reference Citation Analysis]
4 Kaneto H, Koshida R, Baxter M. Fixed‐ratio combination of basal insulin and glucagon‐like peptide‐1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge. Diabetes Obes Metab 2020;22:24-34. [DOI: 10.1111/dom.14095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Yabe D, Iizuka K, Baxter M, Watanabe D, Kaneto H. iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trial. J Diabetes Investig 2021. [PMID: 33945227 DOI: 10.1111/jdi.13563] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Moreno-Juste A, Poblador-Plou B, Aza-Pascual-Salcedo M, González-Rubio F, Malo S, Librero López J, Pico-Soler V, Giménez Labrador E, Mucherino S, Orlando V, Menditto E, Prados-Torres A, Gimeno-Miguel A. Initial Therapy, Regimen Change, and Persistence in a Spanish Cohort of Newly Treated Type 2 Diabetes Patients: A Retrospective, Observational Study Using Real-World Data. Int J Environ Res Public Health 2020;17:E3742. [PMID: 32466267 DOI: 10.3390/ijerph17103742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Komuro I, Kadowaki T, Bodegård J, Thuresson M, Okami S, Yajima T. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases. Diabetes Obes Metab 2021;23 Suppl 2:19-27. [PMID: 33835641 DOI: 10.1111/dom.14119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Terauchi Y, Usami M, Inoue T. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study. Adv Ther 2022;39:2873-88. [PMID: 35449321 DOI: 10.1007/s12325-022-02121-5] [Reference Citation Analysis]
9 Kohsaka S, Kumamaru H, Nishimura S, Shoji S, Nakatani E, Ichihara N, Yamamoto H, Miyachi Y, Miyata H. Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose-lowering agents: A population-based community study from the Shizuoka Kokuho database. J Diabetes Investig 2021;12:1452-61. [PMID: 33345452 DOI: 10.1111/jdi.13485] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Iizuka K, Baxter M, Watanabe D, Yabe D. Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial. Diabetes Obes Metab 2021;23:2795-803. [PMID: 34472693 DOI: 10.1111/dom.14537] [Reference Citation Analysis]
11 Watada H, Takami A, Spranger R, Amano A, Hashimoto Y, Niemoeller E. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial. Diabetes Care 2020;43:1249-57. [PMID: 32295808 DOI: 10.2337/dc19-2452] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 Hirose T, Odawara M, Matsuhisa M, Koshida R, Senda M, Tanaka Y, Terauchi Y. Risk of hypoglycemia in Japanese people with type 2 diabetes mellitus who initiated or switched to insulin glargine 300 U/mL: A subgroup analysis of 12-month post-marketing surveillance study (X-STAR study). Diabetes Res Clin Pract 2021;172:108647. [PMID: 33359753 DOI: 10.1016/j.diabres.2020.108647] [Reference Citation Analysis]